Blood-Based MRD Testing Identifies AML Patients at Risk of Relapse After Stem Cell Transplant

Blood-Based MRD Testing Identifies AML Patients at Risk of Relapse After Stem Cell Transplant

Researchers looked at AML variants in the blood of patients prior to their allogeneic hematopoietic cell transplant and correlated them with subsequent relapse or death.

Read the full article at: www.precisiononcologynews.com

Who We Are

Omnica Corporation is a privately-held design, engineering, and medical product development firm located in Irvine, California. The 28-person company is staffed with full-time employees and has been in operation since 1984. Our speciality is custom product development for the medical industry and industrial fields.

Our expertise is developing complex medical devices.Technical personnel at Omnica includes designers, mechanical engineers, electronic and software engineers, advanced R&D specialists, regulatory staff (for FDA documentation), machinists and model makers.

Learn MoreOmnica Corporation

Leave a Reply

Your email address will not be published. Required fields are marked *